Sales of Oncology Small Molecule Drugs are anticipated To Increase At 5.5% CAGR and Reach US$ 135.4 Billion By 2032

The global oncology small molecule drugs market has reached a valuation of US$ 79 billion in 2022 and is forecasted to expand at a CAGR of 5.5% to climb to a market size of US$ 135.4 billion by 2032.

North America leads the global oncology small molecule drugs market and is expected to contribute more than 50% share over the assessment period (2022-2032).

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.factmr.com/connectus/sample?flag=S&rep_id=3747

The popularity of small molecule cancer medications is steadily rising due to factors such as better overall results, minimal drawbacks, earlier treatment initiation, small drug sizes, etc. Small molecule cancer medications have all of the aforementioned important advantages over other traditional immunotherapies, and the identified clinical trial landscape for them concludes their significance and demand to be thought of as standard therapy.

Owing to these beneficial factors, the oncology small molecule drugs market is expected to offer an absolute $ opportunity of US$ 61.1 billion between 2022 and 2032.

• 𝐒𝐡𝐨𝐫𝐭 𝐓𝐞𝐫𝐦 (𝟐𝟎𝟐𝟐-𝟐𝟎𝟐𝟓): Adoption of small molecule drugs for the treatment of cancer has significantly driven the global market as these drugs notably reduced the mortality rate by overcoming limitations of conventional cancer therapies such as radiation therapy and chemotherapy.

• 𝐌𝐞𝐝𝐢𝐮𝐦 𝐓𝐞𝐫𝐦 (𝟐𝟎𝟐𝟓-𝟐𝟎𝟐𝟖): Improved healthcare services and increment in per-capita spending on healthcare in underdeveloped regions will further contribute to an increase in the sales of small molecule drugs. Regions such as East Asia and MEA will witness incremental opportunistic growth.

• 𝐋𝐨𝐧𝐠 𝐓𝐞𝐫𝐦 (𝟐𝟎𝟐𝟖-𝟐𝟎𝟑𝟐): Small molecule drug demand is forecasted to rise globally due to rigorous research and development in the field of cancer. Personalized targeted drug production and new product launches, along with regulatory approvals, will drive the growth of the market.
Between 2017 and 2021, consumption of oncology small molecule drugs increased at a CAGR of 5.4%. As per the study by Fact.MR, a market research and competitive intelligence provider, the market is projected to progress at 5.5% CAGR between 2022 and 2032.

𝐆𝐞𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬: https://www.factmr.com/connectus/sample?flag=RC&rep_id=3747

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐒𝐦𝐚𝐥𝐥 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐞 𝐃𝐫𝐮𝐠𝐬 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

• 𝐁𝐲 𝐃𝐫𝐮𝐠 𝐂𝐥𝐚𝐬𝐬 :
o Chemotherapy Drugs
• Alkylating Agents
• Antimetabolites
• Other Drugs

𝐨 𝐈𝐦𝐦𝐮𝐧𝐨𝐦𝐨𝐝𝐮𝐥𝐚𝐭𝐢𝐧𝐠 𝐃𝐫𝐮𝐠𝐬

𝐨 𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐃𝐫𝐮𝐠𝐬

• Proteasome Inhibitors
• Tyrosine Kinase Inhibitors
• mTOR Inhibitors
• Others

o 𝐇𝐨𝐫𝐦𝐨𝐧𝐚𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲

• 𝐁𝐲 𝐈𝐧𝐝𝐢𝐜𝐚𝐭𝐢𝐨𝐧 :
o NSCLC
o Renal Cell Carcinoma
o Breast Cancer
o Prostate Cancer
o Multiple Myeloma
o Melanoma
o Lymphoma
o Leukemia
o Others

• 𝐁𝐲 𝐑𝐨𝐀 :
o Oral
o Injectable

• 𝐁𝐲 𝐃𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧 𝐂𝐡𝐚𝐧𝐧𝐞𝐥 :
o Hospital Pharmacies
o Retail Pharmacies
o Specialty Clinics
o Online Pharmacies

• 𝐁𝐲 𝐑𝐞𝐠𝐢𝐨𝐧 :
o North America
o Latin America
o Europe
o East Asia
o South Asia & ASEAN
o Oceania
o MEA

𝐅𝐮𝐥𝐥 𝐀𝐜𝐜𝐞𝐬𝐬 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐈𝐬 𝐀𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐚𝐭: https://www.factmr.com/checkout/3747

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞

Several well-known market players are adopting novel strategies, including ground-breaking marketing strategies, technical developments, mergers, and acquisitions.
Market players such as Novartis AG, Pfizer Inc., Amgen Plc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Company, AbbVie Inc., Bayer AG, Incyte Corporation, Celgene Corporation, AstraZeneca Plc., Exelixis Inc., and Millennium Pharmaceuticals Inc. (Takeda) are utilising sustainable technology and optimization strategies for a variety of end users.

Additionally, manufacturers' primary marketing plans are based on their expertise in planning, coming up with, and delivering the best solutions. Manufacturers in the market also want to expand their product distribution into developing and low-income nations.

• The U.S. Food and Drug Administration granted Novartis AG's Lu-PSMA-617, an investigational radiation therapy for advanced castration-resistant prostate cancer, the classification of 'breakthrough therapy', in June 2021.

• Sanofi and Synthorx, Inc., a clinical-stage biotechnology firm devoted to extending and enhancing the lives of people with cancer and autoimmune illnesses, entered into a formal deal worth roughly US$ 2.5 billion in December 2019.

𝐅𝐨𝐫 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

• https://www.prnewswire.com/news-releases/medical-suction-devices-market-to-register-4-cagr-as-installation-of-ac-powered-machines-surges-in-emergency-care-settings-301632917.html

• https://www.prnewswire.com/news-releases/medical-laser-systems-market-to-exceed-us-7-5-billion-by-2031-amid-higher-acceptance-of-laser-based-plastic-surgery-worldwide-301633977.html

• https://www.prnewswire.com/news-releases/indwelling-catheters-market-to-register-7-2-cagr-through-2031-amidst-growing-prevalence-of-urological-disorders-301638911.html

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com

Market research and consulting agency with a difference! That's why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range - from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we'll be an able research partner.

This release was published on openPR.